Efficacy And Safety Of A Novel Dual Gip And Glp-1 Receptor Agonist Tirzepatide In Patients With Type 2 Diabetes (Surpass-1): A Double-Blind, Randomised, Phase 3 Trial (Vol 398, Pg 143, 2021)